{"url_path":"/sec/aidx/8-k/2026-07-22/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-080432-index.html","accession_number":"0001213900-26-080432","cik":"0001139685","ticker":"AIDX","issuer_name":"20/20 Biolabs, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-080432-index.html","primary_entity_key":"0001139685","primary_entity_name":"20/20 Biolabs, Inc."},"word_count":379,"has_tables":true,"body_markdown":"**Item\n1.01 Entry into a Material Definitive Agreement.**\n\n \n\nAs previously disclosed, on November 17, 2025,\n20/20 Biolabs, Inc. (the “Company”) entered into a securities purchase agreement with Streeterville Capital, LLC (“Streeterville”),\npursuant to which, among other things, the Company agreed to offer and sell to Streeterville up to $40,000,000 of series E convertible\npreferred stock at a purchase price of $1,000 per share. Pursuant to the Certificate of Designation for the series E convertible preferred\nstock (the “Certificate of Designation”), each share of series E convertible preferred stock is convertible at any\ntime at the option of the holder into a number of shares of common stock determined by dividing the stated value of the shares being converted\n($1,098.90 per share) by a conversion price equal to the lower of $11.42 and a price equal to 89% of the lowest daily volume weighted\naverage price of the common stock on its principal market during the ten (10) trading day period prior to the conversion date, but in\nno event lower than a floor price of 20% of the “Minimum Price” as defined in Nasdaq Rule 5635 (subject to adjustment for\nstock splits, stock dividends, stock combinations, recapitalizations or other similar events), calculated as of the most recent issuance\ndate.\n\n \n\nOn July 16, 2026, the Company entered into a standstill\nagreement (the “Standstill Agreement”) with Streeterville, pursuant to which Streeterville agreed that, for the period\nbeginning on the date of the Standstill Agreement and ending on the date that is one hundred twenty (120) days thereafter, it would not\nseek to convert any shares of series E convertible preferred stock into common stock unless on any given trading day the common stock\ntrades at a price that is at least ten percent (10%) greater than the “Minimum Price” as defined in Nasdaq Rule 5635 (the\n“Standstill”); provided that the Standstill shall terminate immediately upon the occurrence of any breach of the Standstill\nAgreement or any Event of Default (as defined in the Certificate of Designation).\n\n \n\nThe foregoing summary of the terms and conditions\nof the Standstill Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Standstill\nAgreement attached as Exhibit 10.1 hereto, which is incorporated herein by reference."}